1259007-88-9

Upstream product

• 1005484-23-0 tert-butyl 2-(4-nitrobenzyl)aziridine 1-carboxylate 
• 1258945-88-8 tert-butyl 2-{[2-(tert-butoxy)-2-oxoethyl]({1-[4-(nitro)phenyl]-3-{4,7,10-tris[2-(tert-butoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododecan-1-yl}propan-2-yl})amino}acetate 
• 1352042-12-6 1-(4-nitrophenyl)-3-(1,4,7,10-tetraazacyclododecan-1-yl)propan-2-amine hydrochloride 
• 1258945-84-4 tert-butyl N-[1-(4-nitrophenyl)-3-(1,4,7,10-tetraazacyclododecan-1-yl)propan-2-yl]carbamate 
• 1258945-85-5 1-(4-nitrophenyl)-3-(1,4,7,10-tetraazacyclododecan-1-yl)propan-2-amine 
• 294-90-6 1,4,7,10-tetraazacyclododecan 

Downstream Products

• 1258945-91-3 2-[(carboxymethyl)[1-(4-isothiocyanatophenyl)-3-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propan-2-yl]amino]acetic acid 
• 1258945-90-2 2-{[1-(4-aminophenyl)-3-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propan-2-yl](carboxymethyl)amino}acetic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates

A new bifunctional ligand C-DEPA was designed and synthesized as a component for antibody-targeted radiation therapy (radioimmunotherapy, RIT) of cancer. C-DEPA was conjugated to a tumor targeting antibody, trastuzumab, and the corresponding C-DEPA-trastu